The Cancer Drug Mechanisms Group combines expertise in cancer biology with drug studies.
Our cancer biology work currently focuses on understanding the development and progression of cancers of the skin and oral cavity. Specifically, we are investigating the molecular mechanisms involved in the progression and metastasis of melanoma, head and neck cancer, as well as cutaneous squamous cell carcinoma. These molecular mechanisms also impact on drug resistance of cancers. The identification and understanding of aberrantly regulated pathways in these cancers is crucial prior to the design or identification of suitable agents to treat the diseases.
Group Leader: Dr Glen Boyle
- Carly Pierce, Research Assistant
- Dr Jacinta Simmons, Research Officer
- Dr Timothy Warren, PhD Student
- Is dual loss of MITF and BRN2 responsible for melanoma treatment insensitivity?
- How are MITF and BRN2 involved in melanoma progression?
If you wish to apply for QIMR Berghofer's student program,
click here for more information.